Carlo Ferrari

Q: What Schools Are Affiliated With Carlo Ferrari

Carlo Ferrari is affiliated with the following schools: University of Milan, University of Parma

Carlo Ferrari's AcademicInfluence.com Rankings

Carlo Ferrari

Computer Science

#8575

World Rank

#9014

Historical Rank

Machine Learning

#3548

World Rank

#3592

Historical Rank

Artificial Intelligence

#3858

World Rank

#3914

Historical Rank

Database

#5573

World Rank

#5782

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Why Is Carlo Ferrari Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Carlo Ferrari's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Hepatitis B virus immunopathogenesis. (1995) (1627)
Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection (2007) (818)
The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T–lymphocyte response (1996) (815)
Statements from the Taormina expert meeting on occult hepatitis B virus infection. (2008) (784)
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. (1996) (722)
PD-1 Expression in Acute Hepatitis C Virus (HCV) Infection Is Associated with HCV-Specific CD8 Exhaustion (2006) (611)
Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells (1994) (565)
The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. (2000) (552)
Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. (1990) (500)
Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. (1998) (477)
T Cells with a CD4+CD25+ Regulatory Phenotype Suppress In Vitro Proliferation of Virus-Specific CD8+ T Cells during Chronic Hepatitis C Virus Infection (2005) (438)
The Role of Virus-Specific Cd8+ Cells in Liver Damage and Viral Control during Persistent Hepatitis B Virus Infection (2000) (438)
Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. (2010) (428)
Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen (1991) (379)
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis (2010) (372)
Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection (2011) (366)
Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. (1999) (361)
CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained (2000) (352)
Lamivudine treatment can overcome cytotoxic T‐cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy (2001) (349)
Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. (1997) (323)
Adaptive immunity in HBV infection. (2016) (323)
HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. (1991) (312)
RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg (2017) (309)
Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. (2012) (307)
Long-lasting memory T cell responses following self-limited acute hepatitis B. (1996) (305)
Dysfunction and functional restoration of HCV‐specific CD8 responses in chronic hepatitis C virus infection (2007) (302)
Early kinetics of innate and adaptive immune responses during hepatitis B virus infection (2009) (282)
Kinetics of the immune response during HBV and HCV infection (2003) (260)
T‐cell response to structural and nonstructural hepatitis C virus antigens in persistent and self‐limited hepatitis C virus infections (1994) (255)
Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. (2003) (244)
Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope (1994) (233)
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways (2015) (233)
Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. (1991) (230)
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. (2006) (230)
IP‐10 predicts viral response and therapeutic outcome in difficult‐to‐treat patients with HCV genotype 1 infection (2006) (225)
Outcome of acute hepatitis C is related to virus‐specific CD4 function and maturation of antiviral memory CD8 responses (2006) (222)
HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis (1993) (221)
Predominant T‐helper 1 cytokine profile of hepatitis B virus nucleocapsid‐specific T cells in acute self‐limited hepatitis B (1997) (219)
Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B (2017) (218)
Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. (2006) (210)
Virus-Specific CD8+ Lymphocytes Share the Same Effector-Memory Phenotype but Exhibit Functional Differences in Acute Hepatitis B and C (2002) (196)
Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. (2002) (193)
Immunopathogenesis of hepatitis C virus infection. (1999) (187)
Activation of natural killer cells during acute infection with hepatitis C virus. (2010) (179)
Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. (2007) (176)
Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms (2011) (172)
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. (2005) (162)
HBV and the immune response (2015) (161)
Intrahepatic, nucleocapsid antigen-specific T cells in chronic active hepatitis B. (1987) (160)
Conserved hepatitis C virus sequences are highly immunogenic for CD4+ T cells: Implications for vaccine development (1999) (155)
Heterologous T cell immunity in severe hepatitis C virus infection (2005) (155)
Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. (2010) (142)
Systemic and intrahepatic interferon‐gamma‐inducible protein 10 kDa predicts the first‐phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C (2010) (138)
Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment. (2008) (129)
Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. (2016) (129)
The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. (2008) (128)
Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. (2017) (126)
Oral lichen planus pathogenesis: A role for the HCV-specific cellular immune response. (2002) (123)
Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL‐AASLD HBV Treatment Endpoints Conference (2019) (122)
Hepatitis B virus immunopathology (2004) (118)
Host Ethnicity and Virus Genotype Shape the Hepatitis B Virus-Specific T-Cell Repertoire (2008) (116)
IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. (2011) (114)
Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV. (2012) (113)
Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. (2006) (108)
The Host–pathogen Interaction during HBV Infection: Immunological Controversies (2010) (108)
TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues. (2018) (104)
Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. (2006) (99)
Republished: Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection (2011) (95)
Functional characterization of cloned intrahepatic, hepatitis B virus nucleoprotein-specific helper T cell lines. (1987) (94)
Immunopathogenesis of hepatitis B. (2003) (85)
Hepatitis B virus structure and biology. (1989) (85)
Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. (2013) (84)
Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis. (2019) (83)
Intrahepatic and circulating HLA class II–restricted, hepatitis C virus–specific T cells: Functional characterization in patients with chronic hepatitis C (2002) (79)
Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma. (2004) (76)
HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). (2007) (76)
Increased Immunostimulatory Activity Conferred to Antigen-presenting Cells by Exposure to Antigen Extract From Hepatocellular Carcinoma After Radiofrequency Thermal Ablation (2008) (75)
Contribution of Herpesvirus Specific CD8 T Cells to Anti-Viral T Cell Response in Humans (2010) (75)
Viral determinants and host immune responses in the pathogenesis of HBV infection (2002) (73)
Natural killer cell phenotype modulation and natural killer/T‐cell interplay in nucleos(t)ide analogue‐treated hepatitis e antigen‐negative patients with chronic hepatitis B (2015) (73)
Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells. (2012) (71)
Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. (2012) (71)
Immunological and Molecular Correlates of Disease Recurrence after Liver Resection for Hepatocellular Carcinoma (2012) (70)
Effects of interferon treatment on the antiviral T‐cell response in hepatitis C virus genotype 1b‐ and genotype 2c‐infected patients (1997) (68)
RNA Interference Therapy With ARC‐520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection (2020) (67)
Hepatitis B virus (HBV)-specific cytotoxic T-cell response in humans: production of target cells by stable expression of HBV-encoded proteins in immortalized human B-cell lines (1992) (66)
Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches (2020) (66)
T Cells with a CD 4 CD 25 Regulatory Phenotype Suppress In Vitro Proliferation of Virus-Specific CD 8 T Cells during Chronic Hepatitis C Virus Infection (2005) (64)
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. (2010) (63)
The preS1 antigen of hepatitis B virus is highly immunogenic at the T cell level in man. (1989) (63)
Molecular features of the hepatitis B virus nucleocapsid T‐cell epitope 18‐27: Interaction with HLA and T‐cell receptor (1997) (61)
Acute phase HBV‐specific T cell responses associated with HBV persistence after HBV/HCV coinfection (2005) (59)
Viral mutations, TCR antagonism and escape from the immune response. (1995) (59)
The Impairment of CD8 Responses Limits the Selection of Escape Mutations in Acute Hepatitis C Virus Infection1 (2005) (58)
HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications (2019) (57)
Epitope specificity of Th0/Th2 CD4+ T-lymphocyte clones induced by vaccination with rHBsAg vaccine. (1997) (51)
Identification of immunodominant hepatitis C virus (HCV)‐specific cytotoxic T‐cell epitopes by stimulation with endogenously synthesized HCV antigens (2001) (50)
Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection (2012) (50)
Fine specificity of the human T-cell response to the hepatitis B virus preS1 antigen. (1992) (50)
HLA and Killer Immunoglobulin-like Receptor Genes as Outcome Predictors of Hepatitis C Virus–Related Hepatocellular Carcinoma (2013) (49)
Cellular immune response to hepatitis B virus antigens. An overview. (1988) (49)
Hepatitis C virus viremia following clinical resolution of acute hepatitis C. (1994) (47)
Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients (2007) (45)
Selective sensitization of peripheral blood T lymphocytes to hepatitis B core antigen in patients with chronic active hepatitis type B. (1986) (43)
Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments (2016) (40)
Serum Ferritin as a Predictor of Treatment Outcome in Patients With Chronic Hepatitis C (2009) (40)
Effector CD8+ T cell-derived interleukin-10 enhances acute liver immunopathology (2017) (40)
Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. (2013) (39)
Antiviral cell-mediated immune responses during hepatitis B and hepatitis C virus infections. (1998) (38)
The influence of T cell cross‐reactivity on HCV‐peptide specific human T cell response (2006) (38)
Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study (2012) (37)
Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection (2020) (36)
Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. (2011) (36)
[Cytokine mediators in acute inflammation and chronic course of viral hepatitis]. (1995) (36)
Strategies to overcome HBV-specific T cell exhaustion: checkpoint inhibitors and metabolic re-programming. (2018) (35)
Digestive and Liver Disease (2011) (35)
A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection (2008) (35)
Does the immune response play a role in the pathogenesis of chronic liver disease? (1988) (31)
The Good and the Bad of Natural Killer Cells in Virus Control: Perspective for Anti-HBV Therapy (2019) (31)
The class I-restricted cytotoxic T lymphocyte response to predetermined epitopes in the hepatitis B and C viruses. (1994) (31)
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts (2017) (29)
PS-080-Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold (2019) (27)
Differential Reductions in Viral Antigens Expressed from CCCDNAVS Integrated DNA in Treatment Naïve HBEAG Positive and Negative Patients with Chronic HBV after RNA Interference Therapy with ARC-520 (2016) (26)
Functional reconstitution of HBV-specific CD8 T cells by in vitro polyphenol treatment in chronic hepatitis B. (2020) (25)
Modeling cost‐effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real‐life cohort (2017) (24)
Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen supression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment (2020) (23)
Is there a role for immunotherapy in hepatocellular carcinoma? (2006) (23)
Role of viral and host factors in HCV persistence: which lesson for therapeutic and preventive strategies? (2004) (22)
A Simplified SARS-CoV-2 Pseudovirus Neutralization Assay (2021) (21)
Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment (2021) (21)
Parenteral exposure to high HIV viremia leads to virus‐specific T cell priming without evidence of infection (2004) (19)
Long-term follow-up of anti-hepatitis C virus antibodies in patients with acute nonA nonB hepatitis and different outcome of liver disease. (2008) (18)
Functional modulation of hepatitis B core antigen-specific T lymphocytes by an autoreactive T cell clone. (1988) (18)
DITTO-HCV early viral kinetics report - novel decline patterns in gen 1 but not gen 2–3 patients treated with PEG-interferon-alfa-2a and ribavirin (2002) (17)
Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen (2017) (17)
Intratumor Regulatory Noncytotoxic NK Cells in Patients with Hepatocellular Carcinoma (2021) (17)
2011 IL28B POLYMORPHISM IS SIGNIFICANTLY CORRELATED WITH IFN ANTI-VIRAL EFFECTIVENESS ALREADY ON FIRST DAY OF PEGYLATED INTERFERON-α AND RIBAVIRIN THERAPY OF CHRONIC HCV INFECTION (2010) (16)
X chromosome contribution to the genetic architecture of primary biliary cholangitis. (2021) (16)
Who is more likely to respond to dual treatment with pegylated‐interferon and ribavirin for chronic hepatitis C? A gender‐oriented analysis (2013) (16)
Assessment of neutrophil gelatinase-associated lipocalin and lactate dehydrogenase in peritoneal fluids for the screening of bacterial peritonitis. (2013) (15)
Energy metabolism and cell motility defect in NK-cells from patients with hepatocellular carcinoma (2020) (15)
T cell regulation in HBV-related chronic liver disease. (2017) (14)
Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection (2013) (14)
Antiviral CD8‐mediated responses in chronic HCV carriers with HBV superinfection (2004) (14)
Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis (2015) (13)
Autopresentation of hepatitis B virus envelope antigens by T cells (1992) (12)
Clonal analysis of intrahepatic T lymphocytes in chronic active hepatitis. Isolation of a T-cell line specific for hepatitis B core antigen from a patient with serological evidence of exposure to HBV. (1986) (12)
The role of neutrophil gelatinase-associated lipocalin (NGAL) in cerebrospinal fluids for screening of acute bacterial meningitis. (2014) (12)
Is Steroid Therapy Needed in the Treatment of Destructive Thyrotoxicosis Induced by α-Interferon in Chronic Hepatitis C? (2005) (12)
DNA Methylation and Immune Cell Markers Demonstrate Evidence of Accelerated Aging in Patients with Chronic HBV or HCV, with or without HIV Co-Infection. (2020) (12)
Cell mediated immune response to hepatitis B virus nucleocapsid antigen. (1993) (11)
Prediction of nonSVR to therapy with pegylated interferon‐α2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment (2010) (10)
Therapeutic vaccination for hepatitis C: can protective T-cell responses be restored after prolonged antigen exposure? (2008) (10)
Evaluation of monoclonality of cell lines from sequential dilution assays. (1987) (10)
Clinical features of hepatitis delta virus infection in a northern italian (2005) (10)
Is antigenic variability a strategy adopted by hepatitis B virus to escape cytotoxic T-lymphocyte surveillance? (1996) (9)
Predicting treatment outcome following 24 weeks peginterferon α‐2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV‐RNA at day 0, day 22, day 29, and week 6 (2007) (9)
Treatment of chronic hepatitis B: Update of the recommendations from the 2007 (2011) (9)
HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study (2016) (8)
Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy. (2008) (8)
A phase 1 study to evaluate safety and tolerability of escalating single doses of the hepatitis B virus RNA interference drug ARC-521 in a healthy volunteer population (2017) (8)
RNA interference therapy with ARC-520 Injection results in long term off-therapy antigen reductions in treatment naïve, HBeAg positive and negative patients with chronic HBV (2018) (8)
Combined GS-4774 and tenofovir therapy can improve HBV-specific T cell responses in patients with chronic active hepatitis B (2017) (7)
T and B cells in hepatitis C virus control: what they do and when they fail. (2007) (7)
Role of the cell-mediated immune response in the pathogenesis of hepatitis B virus infection (2007) (7)
Oral lichen planus pathogenesis: A role for the HCV‐specific cellular immune response (2002) (7)
Comparative pathogenesis of HBV and HCV. (2001) (7)
PreS1 antigen/antibody patterns following interferon therapy in acute and chronic hepatitis B. (1994) (6)
New perspectives for T-cell-based HCV vaccines. (2006) (6)
Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE‐I Part II) (2019) (6)
Graves' Disease in Interferon-α-Treated and Untreated Patients with Chronic Hepatitis C Virus Infection (2005) (6)
HLA class I restricted cytotoxic T cells in acute viral hepatitis type B (1991) (5)
Guidelines for the treatment of chronic viral hepatitis (1997) (5)
Degenerate CD8 Epitopes Mapping to Structurally Constrained Regions of the Spike Protein: A T Cell-Based Way-Out From the SARS-CoV-2 Variants Storm (2021) (5)
Metabolic regulation of the HBV-specific T cell function. (2020) (5)
Immune pathogenesis of hepatitis B. (1992) (5)
Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection (2013) (4)
Course of Graves Disease in Interferon-Treated Patients With Chronic Hepatitis C Virus Infection and in Uninfected Patients (2013) (4)
Proteasome dysfunction as a reversible defect underlying virus-specific CD8 cell exhaustion in chronic hepatitis B (2017) (4)
Predicting HBsAg clearance responses during ARC-520 RNA interference (RNAi) therapy based on HBsAg epitope profile analysis (2016) (4)
Ip-10 Is Associated With Il28b Variation And Predicts The First Phase Decline Of Hcv Rna And Outcome Of Therapy In Chronic Hepatitis C (2010) (3)
Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance (2016) (3)
HCV–Related Mixed Cryoglobulinemia: Data from Piter, a Nationwide Italian HCV Cohort Study (2016) (3)
HCV treatment policy in a real-life cohort (2017) (3)
Gender Differences in HCV Chronic Liver Disease: A Real Life Evaluation in Piter (Piattaforma Italiana per Lo Studio Della Terapia Delle Epatiti Virali) Cohort Study (2016) (3)
Erratum to “Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B”: [J Hepatol 39 (2003) 595–605] (2004) (3)
The cellular immune response to nucleocapsid antigens in hepatitis B virus infection (2004) (3)
Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro (2023) (2)
Corrigendum to “Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: Effect of viremia levels and antiviral treatment” [J Hepatol 48 (2008) 548–558] (2008) (2)
F-45 Rapid virologic response (RVR), IL28B single nucleotide polymorphism (SNP) rs12980275 and HCV genotype are independent predictors of sustained virologic response (SVR) in HIV/HCV coinfected patients treated with pegylated interferon and ribavirin (2012) (2)
What to start with in first line treatment of chronic hepatitis B patients: an Italian multicentre observational cohort, HBV-RER study group. (2017) (2)
Impact of disease severity on outcome of antiviral therapy in treatment‐naïve patients with chronic hepatitis C (2007) (2)
Missed treatment in an Italian HBV infected patients cohort: HBV RER. (2016) (2)
Response prediction in chronic hepatitis C by assessment of IP-10 and IL 28 B-related single nucleotide polymorphisms LAGGING (2017) (2)
The Role of the Cytotoxic T Lymphocyte Response in Hepatitis B Virus Immunobiology and Pathogenesis (1994) (2)
PreS antigen expression and anti-preS response in hepatitis B virus infections: relationship to serum HBV-DNA, intrahepatic HBcAg, liver damage and specific T-cell response. (1992) (2)
494 Analysis of peripheral HCV-specific T cell responses associated with rapid viral decline during PEG-interferon-alfa-2A and ribavirin therapy (DITTO-HCV project) (2004) (1)
[125] PD-1/PD-L BLOCKADE CAN IMPROVE THE HBV-SPECIFIC T CELL FUNCTION IN CHRONIC HBV INFECTION (2007) (1)
The enhancement of NK-cell function after radiofrequency thermal ablation for HCC is predictive of clinical outcome (2009) (1)
DNA Methylation and Immune Cell Markers Demonstrate Evidence of Accelerated Aging in Patients with Chronic Hepatitis B Virus or Hepatitis C Virus, with or without Human Immunodeficienct Virus Co-infection (2021) (1)
Immune Mechanisms of Viral Clearance and Disease Pathogenesis During Viral Hepatitis (2020) (1)
Effective inhibition of cccDNA derived mRNA/viral antigens and tolerability with ARC-520 (2016) (1)
[587] ANTIVIRAL TREATMENT PROFOUNDLY AFFECTS IRON STATUS IN HCV PATIENTS: IMPLICATIONS FOR MANAGEMENT AND TREATMENT OUTCOME (2007) (1)
64 Role of viral escape from cytotoxic T cell surveillance in HCV infection (2004) (1)
120 FUNCTIONAL T CELL RESTORATION INDUCED BY PD-1/PD-L1 BLOCKADE IN CHRONIC HEPATITIS B AND C IS IMPROVED BY SIMULTANEOUS MODULATION OF THE CO-STIMULATORY CD137/CD137L PATHWAY (2009) (1)
DNA methylation and immune cell markers demonstrate evidence of accelerated aging in patients with chronic HBV infection, with improvement during treatment (2018) (1)
Targeting Stress Sensor Kinases in Hepatocellular Carcinoma-Infiltrating Human NK Cells as a Novel Immunotherapeutic Strategy for Liver Cancer (2022) (1)
Interferon (IFN)– g –Inducible Protein–10: Association with Histological Results, Viral Kinetics, and Outcome during Treatment with Pegylated IFN- a 2a and Ribavirin for Chronic Hepatitis C Virus Infection (2006) (1)
T cells can present the hepatitis B virus envelope antigens to themselves (1991) (1)
Molecular basis of Natural Killer cell dysfunction in Hepatocellular Carcinoma (2017) (1)
Association of solid-phase assays to the indirect immunofluorescence in primary biliary cholangitis diagnosis: Results of an Italian multicenter study. (2019) (1)
Metabolic and functional recovery of tumor infiltrating NK-cells in Hepatocellular Carcinoma (2020) (0)
Prevalence of anti-HCV antibodies in patients with acute nonA-nonB viral hepatitis. (1992) (0)
Thermal Ablation for Hepatocellular Carcinoma timulates Autologous NK-Cell Response (0)
Trends in chronic Hepatitis B virus infection in Italy over a 10-year period: clues from the nationwide PITER and MASTER cohorts towards elimination. (2023) (0)
F-43 A multicenter prospective observational study to evaluate factors influencing efficacy, tolerance and compliance to antiviral tretament with interferon and ribavirin in daily clinical practice (2011) (0)
322 KIR AND HLA LOCI AS PREDICTORS OF HCC OUTCOME IN PATIENTS WITH HCV INFECTION (2013) (0)
60 Analysis of HBV-specific T-cell responses in patients with occult HBV infection (2006) (0)
Effect of HBV and HCV coinfection of anti-viral T cell responses (2003) (0)
Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection (2020) (0)
[567] HCV HEPATITIS AND INTERFERON-RELATED DEPRESSION: AN ANALYSIS OF THE RETROSPECTIVE PHASE OF THE PROBE STUDY (2007) (0)
Neoplastic macrovascular invasion represents an independent risk factor for dismal survival in sorafenib treatment for hepatocellular carcinoma (2017) (0)
Treatment prioritization according to the EASL HCV CPG 2015: a real-life evaluation on the PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort (2015) (0)
Characterization of Hepatitis B Virus (HBV)-Speciﬁc T-Cell Dysfunction in Chronic HBV Infection (cid:1) (2007) (0)
F-42 Gender-specific determinants of response in HCV genotype 1 to current SOC with peg IFN and ribavirin in a practice cohort (2012) (0)
Cytotoxic T Lymphocyte Response to a Wild Type Hepatitis B Virus Epitope in Patients Chronically Infected by Variant Viruses Carrying Substitutions (2003) (0)
Longitudinal analysis of HCV-specific CTL responses in acute hepatitis C (2001) (0)
Effect radiofrequency thermal ablation of HCC liver nodules on natural killer cells and regulatory T cells (2007) (0)
Forecasting liver disease burden (2018) (0)
P180 UPREGULATION OF CHROMATIN MODIFYING GENES IN EXHAUSTED T CELLS FROM CHRONIC HBV PATIENTS (2014) (0)
Impact of Soluble CD 26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection (2013) (0)
HEPATITIS B FORUM NEXT STEPS IN TREATING PATIENTS WITH CHRONIC HEPATITIS B: CAN WE CURE THIS DISEASE? (2014) (0)
M1812 Baseline Characteristics and Week-4 Response Among 1546 CHC Patients Infected with HCV Genotype 1, 2, 3 and 4: Interim Results of the Prophesys Cohort (2009) (0)
Hepatitis C virus immunology (2009) (0)
Current epidemiological trends and outcome in a large cohort of acute hepatitis C patients (2005) (0)
NK-cell dysfunction in hepatocellular carcinoma: modulatory approches for functional restoration (2020) (0)
Functional and phenotypic characterization of HBV-specific CD8+ cells during persistent and self-limited HBV infection (2001) (0)
[95] RESTORATION OF CD AND CDS EXHAUSTION BY ANTI-PD-L IN ACUTE HCV INFECTION: A COMPLEMENTARY APPROACH FOR THERAPY? (2007) (0)
P1070 FIRST LINE TREATMENT FOR CHRONIC HEPATITIS B (CH-B) IN REAL LIFE. AN ITALIAN MULTICENTER OBSERVATIONAL COHORT (HBV-RER) (2014) (0)
5 EXHAUSTION AND FUNCTIONAL RESTORATION OF INTRAHEPATIC HBV-SPECIFIC T CELLS IN CHRONIC HEPATITIS B (2008) (0)
353 NATURAL KILLER CELL FUNCTION IS ENHANCED AFTER HCC RADIOFREQUENCY THERMAL ABLATION: RATIONAL FOR THE DEVELOPMENT OF ADJUVANT IMMUNOTHERAPY (2008) (0)
Dynamics and correlates of iron biomarkers in chronic hepatitis C patients undergoing antiviral treatment: an interim report (2006) (0)
Host Ethnicity and Virus Genotype Shape the Hepatitis B Virus-Speciﬁc T-Cell Repertoire (cid:1) † (2008) (0)
Direct antiviral agents therapy can induce a partial restoration of the antiviral immune functions in patients with chronic hepatitis C virus infection (2017) (0)
386 Levels of virus replication and liver inflammation are inversely correlated with the intensity of HBV-specific T cell responses in anti-HBe+ chronic hepatitis B (2006) (0)
[94] PERSISTENT IMPAIRMENT OF HCV-SPECIFIC CDS CELL RESPONSE IN HCV-RNA NEGATIVE PATIENTS AFTER SUCCESSFUL PEG-INTERFERON/RIBAVIRIN TREATMENT (2007) (0)
Imaging , Diagnosis , Prognosis HLA and Killer Immunoglobulin-like Receptor Genes as Outcome Predictors of Hepatitis C Virus – Related Hepatocellular Carcinoma (2013) (0)
[The immunopathogenesis of hepatitis B]. (1992) (0)
[654] PREDICTION OF VIROLOGIC RESPONSE IN HCV GENOTYPE 1A-INFECTED PATIENTS ACCORDING TO AMINO ACID PATTERN IN NS5A USING STATISTICAL LEARNING ALGORITHMS FOR CLASSIFICATION (2007) (0)
1348 VIRAL HETEROGENEITY IN HCV NS5A GENOME IS LOW IN PATIENTS WITH FAVORABLE IL28B GENOTYPES (2011) (0)
121 FUNCTIONAL PARALYSIS OF VIRUS-SPECIFIC T CELLS DURING ACUTE VIRAL HEPATITIS B (2009) (0)
T.N.18 THE HBV-SPECIFIC T CELL FUNCTION CAN BE RECONSTITUTED IN CHRONIC HBV INFECTION: IMPLICATIONS FOR IMMUNE THERAPIES (2010) (0)
T.N.27 TUMOR INFILTRATING CD4 T CELLS AND LIVER INFILTRATING PROINFLAMMATORY T-CELLS AS PREDICTORS OF DISEASE FREE SURVIVAL AFTER RESECTION FOR HCC (2010) (0)
11. Variant-specific and cross-reactive B-cell responses to HCV hypervariable region 1: Relationship to genotype (1997) (0)
P187 INNATE ANTIVIRAL RESPONSES IN HBeAg NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (CH-B) UNDER LONG-TERM NUCLEOS(T)IDE ANALOGUE (NUC) TREATMENT: IMPLICATIONS FOR FUTURE IMMUNE THERAPIES (2014) (0)
697 KIR2DL5 AND HLA-BW4I80 ARE ASSOCIATED WITH LONGER OVERALL SURVIVAL IN PATIENTS UNDERGOING LIVER RESECTION FOR HEPATOCELLULAR CARCINOMA (2012) (0)
F-38 Contrast-enhanced ultrasound and serological biomarkers for early evaluation of clinical outcome of HCC sorafenib treatment (2011) (0)
P0459 : Natural killer cell phenotypic profile in hepatocellular carcinoma (HCC) is predictive of clinical outcome after curative treatment (2015) (0)
Direct visualisation of hepatitis B virus (HBV)-specific cytotoxic T cells with an human leucocyte antigen (HLA) class I peptide tetrameric complex allows a new insight into their actual frequency. (1998) (0)
Cell-mediated Immune Response in Hepatitis C Virus (HCV) Infection: Are Different Strategies Adopted by HCV and Hepatitis B Virus to Persist? (1996) (0)
ctivation of Natural Killer Cells During Acute Infection With epatitis C Virus (0)
Deregulated intracellular pathways define novel molecular targets for HBV-specific CD8 T cell reconstitution in chronic hepatitis B. (2023) (0)
Metabolic signatures of chronic hepatitis C evolution revealed by transcriptome profiling of virus-specific CD8 cells across different stages of HCV infection (2017) (0)
9 Anti-viral T cell response in patients infected simultaneously by HBV and HCV (2003) (0)
O103 TRANSCRIPTOME ANALYSIS OF EXHAUSTED VIRUS-SPECIFIC CD8 T CELLS IN CHRONIC HBV INFECTION IDENTIFIES PROFOUND METABOLIC AND FUNCTIONAL CELL DEFECTS (2014) (0)
Human Leukocyte Antigen and Killer Immunoglobulin-like receptor genes as outcome predictors of hepatitis C virus-related hepatocellular carcinoma (2013) (0)
Radiofrequency thermal ablation of hepatocellular carcinoma (HCC) can enhance NK cell response (2008) (0)
Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort. (2023) (0)
Different proliferative and cytolytic function of memory HBV and HCV-specific cytotoxic T cells in acute hepatitis B and C (2002) (0)
5 BETTER SUSTAINED CONTROL OF CHRONIC GENOTYPE 1 HCV INFECTIONS WITH PEG-IFN ALFA-2A THAN WITH PEG-IFN ALFA-2B TREATMENT: RESULTS OF DAILY CLINICAL PRACTICE (2010) (0)
882 TUMOR LYMPHOCYTIC INFILTRATE: A PREDICTOR OF DISEASE FREE SURVIVAL AFTER RESECTION FOR HCC (2010) (0)
620 Presence of CD4-positive cells in the portal tract on pretreatment liver biopsy is associated with early viral reduction during antiviral treatment of HCV (2006) (0)
Targeting p53 and histone methyltransferases to restore fully exhausted CD8+ T cells in human HCV infection before and after DAA-therapy (2020) (0)
PD-1 Expression in Acute Hepatitis C Virus (HCV) Infection Is Associated with HCV-Speciﬁc CD8 Exhaustion (cid:1) (2006) (0)
Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the ‘underwater portion of the iceberg’ matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries? (2018) (0)
406 Functional impairment of HCV-specific CD8 cells in chronic HCV infection (2004) (0)
Thyroid function in patients with chronic active hepatitis. (1986) (0)
609 BASELINE CHARACTERISTICS AND WEEK-4 RESPONSE AMONG 1546 CHC PATIENTS INFECTED WITH HCV GENOTYPE 1, 2, 3 AND 4: INTERIM RESULTS OF THE PROPHESYS COHORT (2009) (0)
EPITOPE SPECIFICITY OF TH0/TH2 CD4+ T-LYMPHOCYTE CLONES INDUCED BY VACCINATION WITH RHBSAG VACCINE (1997) (0)
Effector CD 8 + T cell-derived interleukin-10 enhances acute liver immunopathology Graphical (2017) (0)
274 ANTIGEN INDEPENDENT FUNCTIONAL SUPPRESSION OF CD8 T CELLS DURING HBV INFECTION (2011) (0)
Perspective study of the antibody response to hepatitis C virus (HCV) antigens in acute nonA-nonB viral hepatitis (1991) (0)
26 Heterologous T cell immunity during severe HCV infection (2004) (0)
413 Functional features of HCV-specific CD8 mediated responses associated with different outcomes of HCV infection (2003) (0)
F-49 Overall survival of patients undergoing liver resection for hepatocellular carcinoma may be predicted by KIR2DL5 and HLA Bw4I80 genotyping (2012) (0)
P155 BLOCKING OF NEGATIVE CO-STIMULATORY PATHWAYS CAN ENHANCE TUMOR-SPECIFIC T-CELL RESPONSE IN HCC PATIENTS UNDERGOING AN IMMUNOTHERAPEUTIC PROTOCOL BASED ON RADIOFREQUENCY THERMAL ABLATION (2014) (0)
Natural heteroclitic-like peptides are generated by SARS-CoV-2 mutations (2022) (0)
Plasma levels of MMP-2, TIMP-1, and PIIIP as markers of liver disease in hepatitis C recurrent after liver transplantation (2001) (0)
Molecular diagnostics in hepatitis C virus infection: clinical applications. Scientific Committee--"Tecnologie molecolari nella diagnostica delle epatopatie" of the Italian Association for the Study of the Liver-AISF. (1997) (0)
558 RESTORATION OF VIRUS SPECIFIC T CELL MEMORY IN CHRONIC HBV INFECTION: IMPLICATIONS FOR OPTIMIZATION OF ANTIVIRAL-THERAPY (2009) (0)
[The cell-mediated antiviral immune response. The possible therapeutic implications for chronic hepatitis B viral infection]. (1995) (0)
Kinetics of the HBV-specific CTL response (1999) (0)
The host–virus relationship is often described by a series of organized virological and immunological events [1]: viral entry, propagation of the virus in the host and early activation of innate immunity followed by maturation (2010) (0)
[407] COMPREHENSIVE ANALYSIS OF HBV GENOTYPE-SPECIFIC T CELL RESPONSE IN GENETICALLY DIFFERENT POPULATIONS PERSISTENTLY INFECTED WITH HBV GENOTYPE B OR D (2007) (0)
40 Protective memory CD8 responses are generated in self-limited but not in persistent HCV infection (2006) (0)
Natural killer cell trafficking dysfunction in hepatocellular carcinoma (2018) (0)
HCV-specific CD 8 cells from sustained viral responders after acute or chronic HCV infection show similar memory phenotypes (0)
Rapid Virologic Response (RVR), IL28B Single Nucleotide Polymorphism (SNP) rs12980275 and HCV genotype are independent predictors of Sustained Virologic Response (SVR) in HIV/HCV coinfected patients treated with Pegylated Interferon and Ribavirin. (2011) (0)
Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (2021) (0)
Low levels of circulating invariant NKT cells predict hepatocellular carcinoma recurrence after curative resection (2009) (0)
ThepreSiAntigen ofHepatitis BVirusIsHighly Immunogenic attheTCellLevelinMan (1989) (0)
O.149 Immunopathogenesis of HBV infection (2006) (0)
[380] RADIOFREQUENCY THERMAL ABLATION OF HEPATOCELLULAR CARCINOMA MAY ACTIVATE REGULATORY T CELLS BLOCKING ANTI-TUMOR T-CELL RESPONSES (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Carlo Ferrari?

Carlo Ferrari is affiliated with the following schools:

Carlo Ferrari's Academic­Influence.com Rankings

Why Is Carlo Ferrari Influential?

Carlo Ferrari's Published Works

Published Works

What Schools Are Affiliated With Carlo Ferrari?

Carlo Ferrari's AcademicInfluence.com Rankings